Logos Global Management LP Karuna Therapeutics, Inc. Transaction History

Logos Global Management LP

$756 Million
Q3 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$161.01 - $317.85 $4.03 Million - $7.95 Million	-25,000 Reduced 21.74%	90,000 $28.5 Million
Q3 2023 Nov 14, 2023	BUY	$164.66 - $218.08 $13.2 Million - $17.4 Million	80,000 Added 228.57%	115,000 $19.4 Million
Q2 2023 Aug 14, 2023	SELL	$176.32 - $240.22 $11.5 Million - $15.6 Million	-65,000 Reduced 65.0%	35,000 $7.59 Million
Q1 2023 May 15, 2023	SELL	$161.33 - $204.36 $8.07 Million - $10.2 Million	-50,000 Reduced 33.33%	100,000 $18.2 Million
Q2 2022 Aug 15, 2022	SELL	$93.97 - $143.33 $17.9 Million - $27.2 Million	-190,000 Reduced 55.88%	150,000 $19 Million
Q1 2022 May 16, 2022	BUY	$98.9 - $132.37 $3.96 Million - $5.29 Million	40,000 Added 13.33%	340,000 $43.1 Million
Q4 2021 Feb 14, 2022	SELL	$110.64 - $159.4 $17.7 Million - $25.5 Million	-160,000 Reduced 34.78%	300,000 $39.3 Million
Q3 2021 Nov 15, 2021	BUY	$101.2 - $125.87 $13.7 Million - $17 Million	135,000 Added 41.54%	460,000 $56.3 Million
Q2 2021 Aug 16, 2021	BUY	$107.45 - $135.95 $13.4 Million - $17 Million	125,000 Added 62.5%	325,000 $37 Million
Q1 2021 May 17, 2021	BUY	$95.46 - $133.08 $7.64 Million - $10.6 Million	80,000 Added 66.67%	200,000 $24 Million
Q4 2020 Feb 16, 2021	BUY	$75.23 - $109.23 $9.03 Million - $13.1 Million	120,000 New	120,000 $12.2 Million
Q2 2020 Aug 14, 2020	SELL	$62.14 - $117.21 $4.33 Million - $8.16 Million	-69,658 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$60.41 - $115.92 $1.81 Million - $3.48 Million	30,011 Added 75.7%	69,658 $5.02 Million
Q4 2019 Feb 14, 2020	BUY	$11.44 - $123.99 $453,561 - $4.92 Million	39,647 New	39,647 $2.99 Million

Others Institutions Holding KRTX

# of Institutions

Shares Held

332K

Call Options Held

Put Options Held

View Full List

About Karuna Therapeutics, Inc.

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

More about KRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Logos Global Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Logos Global Management LP with notifications on news.

Account